Transient Insomnia Clinical Trial
Official title:
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Single-Dose Study of TAK-375 in Healthy Adult Volunteers in a Sleep Lab Model of Transient Insomnia
The purpose of this study is to evaluate the safety and efficacy of Ramelteon, once daily (QD), in healthy subjects within a sleep lab.
Insomnia is characterized by difficulties initiating and maintaining sleep, or of
non-restorative and non-refreshing sleep. Transient insomnia affects approximately one-third
to one-half of the US population, based on the results of 2 surveys of representative
samples of the adult US population conducted by the Gallup Organization in which respondents
were asked if they had "ever had difficulty sleeping." Based on reports of "regular" or
"frequent" sleep difficulty, results from the same studies suggest that approximately
one-tenth of the US population experiences chronic insomnia. The ideal treatment for
insomnia would reduce the latency to onset of sleep and increase total sleep time, without a
negative impact on sleep architecture and without safety concerns or next-day effects.
Ramelteon is a selective melatonin-1 receptor agonist under global development by Takeda
Chemical Industries, Ltd., for the treatment of transient and chronic insomnia and for the
treatment of Circadian Rhythm Sleep Disorders.
This study is being conducted to evaluate the safety and efficacy of a single dose of
Ramelteon in normal healthy subjects in a sleep lab model of transient insomnia.
Participation is this study is anticipated to be about 3 weeks.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03331042 -
SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.
|
Phase 3 | |
| Completed |
NCT00594022 -
Evaluation of Vestibular Stimulation to Help Occasional Sleeplessness
|
N/A | |
| Completed |
NCT00163046 -
A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
|
Phase 3 | |
| Completed |
NCT00666770 -
A Polysomnographic Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
|
Phase 3 | |
| Completed |
NCT00666939 -
A Study of Single-Dose Gabapentin in Subjects With Transient Insomnia Induced by a Sleep Phase Advance
|
Phase 3 | |
| Completed |
NCT00667108 -
A Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
|
Phase 3 | |
| Recruiting |
NCT05457790 -
Feasibility and Preliminary Efficacy of Acceptance and Commitment Therapy (ACT) for Sleep Disturbances in Adults With Sickle Cell Disease (SCD)
|
N/A | |
| Not yet recruiting |
NCT04396327 -
SM-1 vs. an Active Comparator in A Model of Transient Insomnia
|
Phase 2 | |
| Withdrawn |
NCT03338764 -
An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History of Transient Insomnia
|
Phase 3 | |
| Completed |
NCT01779830 -
A Study of LY2624803 in Participants With Transient Insomnia
|
Phase 1 | |
| Completed |
NCT00674752 -
A Polysomnographic Study Of Single-Dose Gabapentin In Transient Insomnia
|
Phase 3 | |
| Completed |
NCT00666575 -
A Study of the Safety of Gabapentin in a Potential Over-the-Counter Population With Occasional Sleeplessness
|
Phase 3 | |
| Completed |
NCT00659100 -
A Trial to Assess Consumer Self-Selection and Use of Gabapentin for Occasional Sleeplessness in an Over-the-Counter Environment
|
Phase 3 |